| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9617258 | PFIZER | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
Dec, 2034
(10 years from now) | |
Litfulo is owned by Pfizer.
Litfulo contains Ritlecitinib Tosylate.
Litfulo has a total of 1 drug patent out of which 0 drug patents have expired.
Litfulo was authorised for market use on 23 June, 2023.
Litfulo is available in capsule;oral dosage forms.
Drug patent challenges can be filed against Litfulo from 24 June, 2027.
The generics of Litfulo are possible to be released after 03 December, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 23, 2028 |
Drugs and Companies using RITLECITINIB TOSYLATE ingredient
NCE-1 date: 24 June, 2027
Market Authorisation Date: 23 June, 2023
Treatment: NA
Dosage: CAPSULE;ORAL
More Information on Dosage
LITFULO family patents
